FAQ

Male Infertility stem cell therapy — your questions answered (2026)

Medical review statusPending clinical sign-offLast evidence update: 2026-08-05Methodology and editorial standards
Clinical review team: Dr Kamelia Milcheva, Hematologist · Dr Vadym Uvarov, Board-Certified Physician · Hepatobiliary Surgeon · Candidate of Medical SciencesEditorial responsibility: StemCellAtlas research teamEducational information only. This page does not provide medical advice, diagnosis or a treatment recommendation.

About stem cell therapy for Male Infertility

Male infertility can result from impaired sperm production, obstruction, hormonal or genetic disorders, infection, medicines, systemic disease or unexplained factors. Cell research includes laboratory generation or support of germ cells, but this is not equivalent to clinically proven restoration of fertility. MSC, testicular-cell and exosome products have different risks and must not be grouped under one regenerative label.

The evidence for Male Infertility

Evaluation should establish semen findings, medical and reproductive history, examination and, when indicated, hormonal or genetic testing. The NICHD male-infertility treatment overview describes cause-specific medicines or surgery and assisted reproductive technologies. A laboratory marker or reported sperm-count change after an investigational product does not by itself show pregnancy or live-birth benefit.

Separate diagnostic work-up, product, procedure, cryostorage, assisted reproduction, partner treatment, travel, follow-up and complication care. A cell-procedure quote cannot be compared with IVF or other established pathways without accounting for pregnancy and live-birth outcomes and costs for both partners.

Can stem cells improve sperm production?

Cell therapy for Male Infertility may be offered as an individualised programme, but regulatory status depends on the product, processing, indication and jurisdiction. It is currently investigational. Verify authorisation status, cell source, release testing and clinical evidence for the specific proposal.

Which cases qualify?

Schedules vary by the exact product, protocol, route, monitoring needs and clinical context. Request the proposed schedule and its evidence before making travel arrangements.

Realistic chances?

Eligibility depends on the protocol's inclusion and exclusion criteria and an appropriately qualified clinician's assessment. An online checklist cannot determine candidacy or replace medical advice.

EU cost?

The partner-published indicative range for an Male Infertility programme is €3,000–€8,000 for treatment. Request a current written quotation and compare product, dose, visits, inclusions and follow-up before using country ranges as a benchmark.

Sources & further reading

We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.

Before deciding, verify the exact product, legal route, evidence, risks, alternatives and total cost. An online checklist is educational only and cannot determine candidacy.

← Back to Male Infertility overview · Male Infertility cost →

Explore all sections · Data & downloads

Compare cell-therapy evidence, registered studies and published price observations.

StemCellAtlas is a source-first research and cost-planning guide. It separates registry and regulator evidence from heterogeneous commercial observations.

Request written information